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Physical frailty and sarcopenia (PF&S) is a prototypical geriatric condition characterized
by reduced physical function and low muscle mass. The multifaceted pathophysiology
of this condition recapitulates all hallmarks of aging making the identification of
specific biomarkers challenging. In the present study, we explored the relationship
among three processes that are thought to be involved in PF&S (i.e., systemic
inflammation, amino acid dysmetabolism, and mitochondrial dysfunction). We took
advantage of the well-characterized cohort of older adults recruited in the “BIOmarkers
associated with Sarcopenia and Physical frailty in EldeRly pErsons” (BIOSPHERE)
study to preliminarily combine in a multi-platform analytical approach inflammatory
biomolecules, amino acids and derivatives, and mitochondrial-derived vesicle (MDV)
cargo molecules to evaluate their performance as possible biomarkers for PF&S.
Eleven older adults aged 70 years and older with PF&S and 10 non-sarcopenic
non-frail controls were included in the analysis based on the availability of the three
categories of biomolecules. A sequential and orthogonalized covariance selection—linear
discriminant analysis (SO-CovSel–LDA) approach was used for biomarkers selection.
Of the 75 analytes assayed, 16 had concentrations below the detection limit. Within
the remaining 59 biomolecules, So-CovSel–LDA selected a set comprising two amino
acids (phosphoethanolamine and tryptophan), two cytokines (interleukin 1 receptor
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antagonist and macrophage inflammatory protein 1β), and MDV-derived nicotinamide
adenine dinucleotide reduced form:ubiquinone oxidoreductase subunit S3 as the best
predictors for discriminating older people with and without PF&S. The evaluation of these
biomarkers in larger cohorts and their changes over time or in response to interventions
may unveil specific pathogenetic pathways of PF&S and identify new biological targets
for drug development.
Keywords: aging, biomarkers, cytokines, extracellular vesicles, geroscience, metabolomics, mitochondrial
dysfunction, mitochondrial quality control
INTRODUCTION
Sarcopenia is the progressive decline in muscle mass and
strength that accompanies aging (Marzetti et al., 2017). This
condition exposes older adults to a high risk of negative
health-related events, including disability, loss of independence,
institutionalization, and death (Marzetti et al., 2017). The public
health relevance of sarcopenia is widely recognized and so is
the need for effective preventive and therapeutic interventions
(Beaudart et al., 2014). Yet, the heterogeneous phenotypic
presentation of sarcopenia, the insufficient understanding of its
pathophysiology, and the frequent superimposition of other age-
related conditions have hampered the study of sarcopenia as a
standalone phenomenon (Calvani et al., 2018a). This impasse
is also reflected by the lack of a unique operational definition
of sarcopenia (Landi et al., 2018) and clinically meaningful
biomarkers (Calvani et al., 2017). In this scenario, the recently
defined “physical frailty and sarcopenia” (PF&S) syndrome has
marked a major step forward for the clinical and regulatory
recognition of the condition (Cesari et al., 2017).
When digging into the pathways and processes involved in
PF&S pathophysiology, several factors spanning from muscle-
specific mitochondrial dysfunction to systemic changes (e.g.,
inflammation, amino acid dysmetabolism) have been pinpointed
(Marzetti et al., 2016, 2019; Picca et al., 2017a; Calvani et al.,
2018b). Whether these processes share common roots and how
cell-based alterations spread and are sensed at the systemic
level are presently unknown. Small extracellular vesicle (sEVs)
of mitochondrial origin, termed mitochondrial-derived vesicles
(MDVs), have recently been proposed as possible shuttles across
biological systems (Picca et al., 2020a). However, little is known
about their complex regulatory network.
The pathophysiology of PF&S recapitulates all hallmarks of
aging (López-Otín et al., 2013; Sierra, 2016; Justice et al., 2018).
Hence, PF&S is considered to be a prototypical geroscience
conditions for which a strong interdependence and non-linear
relationships between biomarkers may be envisioned (Cohen
et al., 2018). In such a scenario, the analysis of single pathways
enlightening discrete aspects of the condition and, thus, setting
aside its multifaceted nature, might neglect relevant information
(Cohen et al., 2018; Justice et al., 2018). This limitation could
be overcome through the adoption of multivariate analytical
strategies that enable the exploitation of more comprehensive,
multi-platform datasets (Calvani et al., 2015). In the present
preliminary study, we took advantage of the well-characterized
cohort of older adults recruited in the “BIOmarkers associated
with Sarcopenia and Physical frailty in EldeRly pErsons”
(BIOSPHERE) study (Calvani et al., 2018b,c; Marzetti et al., 2019;
Picca et al., 2019a, 2020a) to simultaneously analyze biomediators
pertaining to three different domains: inflammation, amino
acid metabolism, and mitochondrial quality control (MQC).
The availability of systemic inflammatory and metabolic data
from this cohort (Calvani et al., 2018b; Marzetti et al., 2019)
and their complementation with the analysis of circulating
MDVs (Picca et al., 2020a) provided a composite dataset
to explore the relationship among systemic inflammation,
metabolic characteristics, and MDV trafficking in PF&S. Data
analysis was performed through sequential and orthogonalized
covariance selection coupled with linear discriminant analysis
(SO-CovSel–LDA), an innovative analytical strategy that is
particularly suited for dealing with multi-block datasets (i.e.,
experimental settings in which variables are assayed using
different platforms and/or at different time points) (Biancolillo
et al., 2020). SO-CovSel–LDA enabled selecting the variables
of interest for PF&S from a large number of highly correlated
candidate biomarkers. The evaluation of these biomarkers in
larger cohorts and their changes over time or in response to
interventions may unveil specific pathophysiological pathways of
PF&S and identify biological targets for drug development.
MATERIALS AND METHODS
Participants
Participants of the present study were community-dwellers
aged 70+ with PF&S and non-sarcopenic non-frail (nonPF&S)
controls from the BIOSPHERE cohort (Calvani et al., 2018c).
BIOSPHERE is a cross-sectional study conceived for selecting
and validating a panel of candidate biomarkers for PF&S through
multivariate statistical modeling (Calvani et al., 2018b,c; Picca
et al., 2019a).
To diagnose PF&S, the operational definition developed in
the “Sarcopenia and Physical fRailty IN older people: multi-
componenT Treatment strategies” (SPRINTT) project (Marzetti
et al., 2015, 2018) was applied: (a) physical frailty, based on
a summary score on the Short Physical Performance Battery
(SPPB) (Guralnik et al., 1994) between 3 and 9; (b) low
appendicular muscle mass (aLM), according to the cut-points of
the Foundation for the National Institutes of Health Sarcopenia
Project (Studenski et al., 2014); and (c) absence of major mobility
disability (i.e., inability to complete a 400-m walk test) (Newman
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et al., 2006). Data analysis for the present investigation was
conducted in a convenience sample of 21 participants (11 older
adults with PF&S and 10 nonPF&S controls) for whom complete
data were available for inflammatory and metabolic mediators
and MDV characterization.
The Ethics Committee of the Università Cattolica del Sacro
Cuore (Rome, Italy; protocol number BIOSPHERE: 8498/15)
approved the study protocol. All procedures were conducted
in compliance to the ethical standards laid down in the
1964 Declaration of Helsinki and its later amendments. Study
procedures and criteria for participant selection were described
thoroughly elsewhere (Calvani et al., 2018c). A written inform
consent form was signed by all participants prior to enrolment.
Assessment of Appendicular Lean Mass by
Dual X-Ray Absorptiometry
Appendicular lean mass was quantified through whole-body
dual X-ray absorptiometry scans on a Hologic Discovery A
densitometer (Hologic, Inc., Bedford, MA, USA) according to the
manufacturer’s directions. Criteria for low aLM were as follows:
(a) aLM to body mass index (BMI) ratio (aLMBMI) <0.789 and
<0.512 in men and women, respectively; or (b) crude aLM
<19.75 kg in men and <15.02 kg in women when the aLMBMI
criterion was not met (Studenski et al., 2014).
Collection and Processing of Blood
Samples
Blood samples were obtained in the morning after overnight
fasting by venipuncture of the median cubital vein, using
BD Vacutainer R© commercial tubes (Becton, Dickinson and
Co., Franklin Lakes, NJ, USA). One tube was delivered
to the centralized diagnostic laboratory of the Fondazione
Policlinico Universitario “Agostino Gemelli” IRCCS (Rome,
Italy) for standard blood biochemistry. The remaining tubes were
processed for serum separation in the Biogerontology lab of
the Università Cattolica del Sacro Cuore. After 30min of blood
clotting at room temperature, samples were centrifuged at 1,000
× g for 15min at 4◦C. The upper clear fraction (serum) was
recovered in 0.5-mL aliquots and stored at−80◦C until analysis.
Purification of Small Extracellular Vesicles
From Serum
Small EVs were purified from serum through differential
centrifugation and were quantified as previously reported (Picca
et al., 2018a, 2019b, 2020a). In brief, serum samples were diluted
with equal volumes of phosphate-buffered saline (PBS) and
centrifuged at 2,000 × g at 4◦C for 30min. Supernatants were
collected and centrifuged at 12,000× g at 4◦C for 45min to
remove apoptotic bodies, mitochondrial fragments, cell debris,
and vesicles larger than 200 nm. Supernatants were subsequently
ultracentrifuged at 110,000× g at 4◦C for 2 h. Pellets were
recovered and resuspended in PBS, filtered through a 0.22-µm
filter and ultracentrifuged at 110,000 × g at 4◦C for 70min to
eliminate contaminant proteins. Pellets enriched in purified sEVs
were finally resuspended in 100 µL of PBS. To quantify sEVs,
TABLE 1 | Composition of the biomarker panel.
Biological
pathways
Biomolecules
Inflammation BDNF, CRP, IL1-β, IL1-ra, IL2, IL4, IL5, IL6, IL7, IL8, IL9,
IL10, IL12, IL13, IL15, IL17, FGF basic, FGF21, G-CSF,
GM-CSF, IFN-γ, MCP-1, MIP-1α, MIP-1β, CCL5,
CCL11, IP-10, MPO, PDGF-BB, TNF-α, VEGF
Amino acid
metabolism
1-methylhistidine, 3-methylhistidine, 4-hydroxyproline,
α-aminobutyric acid, β-alanine, β-aminobutyric acid,
γ-aminobutyric acid, alanine, aminoadipic acid, anserine,
arginine, asparagine, aspartic acid, carnosine, citrulline,
cystathionine, cystine, ethanolamine, glutamic acid,
glycine, histidine, isoleucine, leucine, lysine, methionine,
ornithine, phenylalanine, phosphoethanolamine,
phosphoserine, proline, sarcosine, serine, taurine,
threonine, tryptophan, tyrosine, valine
MDVs ATP5A, CD63, MTCOI, NDUFB8, NDUFS3, SDHB,
UQCRC2
ATP5A, adenosine triphosphate 5A; BDNF, brain-derived neurotrophic factor; CCL,
C-C motif chemokine ligand; CD, cluster of differentiation; CRP, C-reactive protein;
FGF, fibroblast growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF,
granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; IL1-
ra, IL1 receptor agonist; IP, IFN-α-induced protein; MCP-1, monocyte chemoattractant
protein 1; MDVs, mitochondrial-derived vesicles; MIP-1α, macrophage inflammatory
protein 1α; MIP-1β, macrophage inflammatory protein 1β; MPO, myeloperoxidase;
MTCOI, mitochondrial cytochrome C oxidase subunit I; NDUFB8, nicotinamide adenine
dinucleotide reduced form (NADH):ubiquinone oxidoreductase subunit B8; NDUFS3,
NADH:ubiquinone oxidoreductase subunit S3; PDGF-BB, platelet-derived growth factor
BB; SDHB, succinate dehydrogenase complex iron sulfur subunit B; TNF-α, tumor
necrosis factor alpha; UQCRC2, ubiquinol-cytochrome C reductase core protein 2; VEGF,
vascular endothelial growth factor.
total protein concentration was measured using the Bradford
assay (Théry et al., 2006).
Measurement of Inflammatory, Metabolic,
and Mitochondrial Markers
Serum samples were assayed for a panel of 75 candidate
biomarkers (Table 1). The panel was designed based on
previous studies in older adults and their involvement in
pathways and processes relevant to PF&S pathophysiology
(i.e., inflammation, amino acid metabolism, and mitochondrial
dysfunction) (Calvani et al., 2018b, 2020a; Marzetti et al., 2019;
Picca et al., 2019a, 2020b).
Twenty-seven inflammatory mediators including cytokines,
chemokines, and growth factors were assayed using the Bio-
Plex ProTM Human Cytokine 27-plex Assay kit (#M500KCAF0Y,
Bio-Rad Laboratories Inc., Hercules, CA, USA) on a Bio-
Plex R© System with Luminex xMAP R© Technology (Bio-Rad
Laboratories), as described elsewhere (Ponziani et al., 2018,
2019; Marzetti et al., 2019; Picca et al., 2019a; Addolorato
et al., 2020). Serum levels of C-reactive protein (CRP),
myeloperoxidase (MPO), fibroblast growth factor (FGF) 21, and
brain-derived neurotrophic factor (BDNF) were measured by
using commercially available kits on an ELLATM automated
immunoassay system (Bio-Techne, San Jose, CA, USA). The
concentration of 37 amino acids and derivatives was determined
by ultraperformance liquid chromatography/mass spectrometry
(UPLC/MS) as described previously (Calvani et al., 2018b).
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Protein levels of tetraspanin CD63 and selected mitochondrial
markers were measured by Western immunoblot analysis in
purified sEVs, as detailed elsewhere (Picca et al., 2020a).
According to the guidelines of the International Society
of Extracellular Vesicles (Théry et al., 2018), sEV purity
was ascertained by verifying the presence of the cytosolic
protein flotilin (positive control) and the absence of the non-
sEV component heterogeneous nuclear ribonucleoprotein A1
(HNRNPA1, negative control). Scanning electron microscopy
analyses were performed to confirm enrichment in sEVs
(Théry et al., 2018).
Statistical Analysis
Descriptive Statistics
Descriptive statistics were run on all data. The normal
distribution of data was ascertained via the Kolmogorov–
Smirnov test. Differences in demographic, anthropometric,
clinical, and biological parameters between participants with and
without PF&S were assessed via t-test statistics or the Mann–
Whitney U-test, as appropriate, for continuous variables. Chi-
squared χ2 or Fisher exact tests were applied for categorical
variables. All tests were two-sided, with statistical significance set
at p < 0.05. Analyses were performed using the GraphPrism 5.03
software (GraphPad Software, Inc., San Diego, CA, USA).
Sequential and Orthogonalized Covariance
Selection – Linear Discriminant Analysis
In order to identify relationships among different sets of
data and to identify putative markers of PF&S, a recently
proposed multi-block classification approach, called SO-CovSel–
LDA (Biancolillo et al., 2020), was adopted. SO-CovSel–LDA
is a highly efficient multi-block classification strategy, which
combines a very parsimonious variable selection algorithm
to be applied on each individual block (CovSel) (Roger
et al., 2011) with the sequential inclusion of data matrices,
after orthogonalization with respect to the previously selected
variables. This procedure reduces redundancies among the
blocks and allows a clearer interpretation of results.
Here, we begin with describing the CovSel variable selection
algorithm for a single block of predictors X to make its
generalization to the case of multiple blocks easier to follow.
CovSel allows selecting the minimum number of variables that
provide an accurate regression model between the X matrix and
a response Y. Variables are progressively selected from the X-
block as those having maximum covariance with Y. Parsimony
is achieved as any successive predictor is selected after both X
and Y are orthogonalized with respect to the previously chosen
variables, so to bring as much new information as possible.
SO-CovSel is a generalization of this procedure to a multi-
block case, enriched by the concept of sequential inclusion
of the blocks after orthogonalization which is borrowed from
methods such as SO partial least squares (SO-PLS) regression
(Biancolillo and Næs, 2019; Biancolillo et al., 2019). In the case
of three blocks of predictors, like in the present study (i.e.,
inflammatory markers, amino acids, and MDV cargo molecules),
the SO-CovSel algorithm proceeds as follows. Variables are
selected from the first block (amino acids and derivatives) using
CovSel, then both the second block (inflammatory markers) X2
and theY are orthogonalized with respect to the variables selected
from the first block (X1,sel):
X2, orth =
[
I− X1,sel
(
XT1, selX1,sel
)−1
XT1, sel
]
X2 (1)
Yorth =
[
I− X1,sel
(
XT1, selX1,sel
)−1
XT1, sel
]
Y (2)
where I is the identity matrix and the superscript T indicates
matrix transposition. CovSel is then applied to the matrix
X2, orth to select variables having maximum covariance with
Yorth; the selected variables are subsequently collected in the
matrix X2,sel. The third block (MDV markers) and the Y are
orthogonalized with respect to the variables selected from the
first two blocks, similar to what described in equations (1) and
(2). CovSel is applied to the orthogonalized third block X3, orth
to select variables (X3,sel) with maximum covariance with the
orthogonalized response. Finally, an overall regression model is
built between the selected variables from the three blocks and
the Y:
Ŷ = X1,selB1 + X2,selB2 + X3,selB3 Y (3)
where Ŷ is the predicted response and B1, B2, and B3 are the
regression coefficients.
SO-CovSel–LDA is the classification analog of the SO-CovSel
regression algorithm. As such, it requires the class information
to be encoded in a binary-coded response vector y. The
response vector will have the value 1 for PF&S participants
and 0 for nonPF&S controls. A SO-CovSel model is built
between the different blocks of predictors and the y as described
above. Eventually, LDA is applied to the predicted response to
accomplish sample classification.
To unbiasedly validate the results, a repeated double cross-
validation (rDCV) procedure was used (Smit et al., 2007;
Biancolillo et al., 2019). DCV consists of two loops of cross-
validation nested into one another: the inner loop is used for
model selection and the outer loop for external validation (i.e.,
contains samples that were not use at any stage of model
building or optimization). Since DCV implies splitting the
samples into the different cross-validation groups, to avoid the
outcomes depending on a particular splitting scheme, the whole
procedure is repeated a certain number of times (50 in the
present study). In the context of biomarker discovery, the use
of rDCV has the advantage that many different models are
calculated (as many as the product of the number of DCV runs
times the number of splits in the inner loop), which enables
evaluating how consistently variables are selected by SO-CovSel–
LDA and how robust candidate markers are. All calculations
were carried out using in-house written functions running
under Matlab environment (R2015b, The Mathworks, Natick,
MA) and freely downloadable at: https://www.chem.uniroma1.it/
romechemometrics/research/algorithms/so-covsel/.
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TABLE 2 | Participant characteristics according to the presence of physical frailty
& sarcopenia.
Characteristic nonPF&S
(n = 10)
PF&S
(n = 11)
p-value
Age (years), mean ± SD 73.9 ± 2.7 77.7 ± 5.4 0.0557
Gender (female), n (%) 5 (50) 8 (73) 0.5344
BMI (kg/m2 ), mean ± SD 28.1 ± 2.8 30.3 ± 4.3 0.1891
SPPB summary score,
mean ± SD
12.0 ± 1.0 7.0 ± 0.3 <0.0001
aLM (kg), mean ± SD 20.21 ± 4.10 15.84 ± 3.63 0.0390
aLMBMI, mean ± SD 0.81 ± 0.32 0.51 ± 0.11 0.0118
Albumin (g/L), mean ± SD 45.4 ± 12.7 39.8 ± 1.2 0.1536
Total serum protein
concentration (g/L), mean ± SD
71.8 ± 4.6 75.5 ± 3.1 0.0914
Neutrophil count (109/L) 3.46 ± 1.40 4.07 ± 1.10 0.2757
Lymphocyte count (109/L) 1.76 ± 0.41 1.37 ± 0.30 0.0222
Neutrophil/lymphocyte 1.94 ± 0.57 3.13 ± 1.14 0.0076
Number of diseases*,
mean ± SD
3.2 ± 1.6 3.1 ± 1.2 0.8647
Number of medications§,
mean ± SD
2.9 ± 1.6 3.2 ± 1.8 0.7061
aLM, appendicular lean mass; aLMBMI, aLM adjusted by body mass index (BMI);
nonPF&S, non-physically frail, non-sarcopenic; PF&S, physical frailty & sarcopenia; SD,
standard deviation.
*Includes hypertension, coronary artery disease, prior stroke, peripheral vascular disease,
diabetes, chronic obstructive pulmonary disease, and osteoarthritis.
§ Includes prescription and over-the-counter medications.
RESULTS
Characteristics of the Study Participants
Data from 21 BIOSPHERE participants, 11 older adults with
PF&S (mean age 77.7 ± 5.4 years; 73.0% women) and 10
nonPF&S controls (mean age 73.9 ± 2.7 years; 50.0% women)
were analyzed in the present study. Demographic, functional,
anthropometric, and clinical characteristics of the included
participants were comparable to those of the whole BIOSPHERE
cohort (Marzetti et al., 2019).
As shown in Table 2, no differences were observed in sex
distribution, BMI, or number of comorbid conditions and
medications between PF&S and controls participants. The latter
group was slightly younger, but the age difference did not
reach statistical significance. Serum albumin, total serum protein
concentration, and the neutrophil count were comparable
between groups. On the other hand, the lymphocyte count was
lower and the neutrophil-to-lymphocyte ratio was higher in the
PF&S group. As per the inclusion criteria adopted, participants
with PF&S had lower SPPB scores and smaller aLM either crude
or adjusted by BMI compared with nonPF&S controls.
Biomarker Selection Through
SO-CovSel–LDA Analysis
Serum levels of 75 inflammatory cytokines, growth factors,
neurogenesis and neural plasticity mediators, amino acids and
derivatives, and MDV cargo molecules were measured through
multiple analytical platforms. Of the assayed biomolecules,
concentrations of anserine, carnosine, cystathionine, γ-
aminobutyric acid, phosphoserine, interleukin (IL) 2, IL5, IL7,
IL10, IL13, IL15, granulocyte colony-stimulating factor, vascular
endothelial growth factor, mitochondrial cytochrome C oxidase
subunit I, nicotinamide adenine dinucleotide reduced form
(NADH):ubiquinone oxidoreductase subunit B8, and ubiquinol-
cytochrome C reductase core protein 2 were below the detection
limit. Serum concentrations of the assayed biomolecules are
shown in Supplementary Table 1. SO-CovSel–LDAmodels were
built using a multi-matrix dataset containing 59 analytes. Serum
concentrations of candidate biomarkers were organized into
three matrices according to the analytical approach adopted for
their determination and the biological domain of pertinence
(Table 1). Prior to data analysis, blocks were individually
pretreated by autoscaling through subtracting from each variable
its mean and dividing the result by its standard deviation.
Afterwards, SO-CovSel–LDA models were built and validated
via 50 runs of rDCV with 21 cancelation groups in the outer loop
and five in the inner loop. The optimal order of blocks and the
optimal number of variables from each block were selected as
those returning the smallest error in the inner cross-validation
loop. Since a total of 50 × 21 (i.e., 1,050) different models were
built, the procedure allowed calculating the confidence intervals
for the predictive ability and the consistency of selection of the
optimal number of predictors as well as revealing their identity.
The predictive ability was evaluated on the samples of
the outer rDCV loop, since they were completely external
of the models used for their prediction, thereby providing
more unbiased estimates of the discriminant capacity. Our
analytical approach was able to correctly classify 87.5 ± 7.3%
of PF&S participants and 83.6 ± 9.2% of nonPF&S controls,
corresponding to an overall classification accuracy of 85.6
± 5.0%. Permutation tests with 1,000 randomizations, which
describe the distribution of figures of merit under the null
hypothesis, showed that the discriminant ability of the model was
statistically significant (p < 0.001).
Results appeared to be highly consistent across rDCV runs.
Indeed, in all of the 1,050 models calculated, the best order of
the blocks was found to be (1) amino acids and derivatives,
(2) inflammatory biomolecules, and (3) MDV markers. In the
large majority of iterations, the optimal model complexity was
found to be 2, 2, and 1 variables, respectively. Figure 1 illustrates
the frequency of selection of discriminant markers across the
1,050 models calculated during the rDCV procedure. The figure
shows that the optimal model complexity was consistently
found to be 2-2-1, and that the same biomolecules—i.e.,
phosphoethanolamine, tryptophan, IL1 receptor antagonist (IL1-
ra), macrophage inflammatory protein 1β (MIP-1β), and NDUF
subunit S3 (NDUFS3)—were selected in almost all iterations,
thus confirming the robustness of the proposed biomarkers in
our sample.
DISCUSSION
According to the geroscience paradigm, the roots of most
chronic diseases reside in perturbations of a discrete set
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FIGURE 1 | Discriminant biomolecules selected by sequential and orthogonalized covariance selection coupled with linear discriminant analysis (SO-CovSel–LDA).
Candidate biomarkers are presented according to the order in which they respective data matrices were entered into the model: (A) amino acids and derivatives,
(B) inflammatory biomolecules, and (C) mitochondrial-derived vesicle cargo molecules. IL1-ra, interleukin 1 receptor agonist; MIP-1β, macrophage inflammatory
protein 1β; NDFUS3, nicotinamide adenine dinucleotide reduced form (NADH), ubiquinone oxidoreductase subunit S3.
of biological mechanisms, collectively termed hallmarks
of aging (López-Otín et al., 2013). The pathophysiology
of sarcopenia involves all major biological pillars of aging
and is, therefore, envisioned as a prototypical geroscience
condition (Calvani et al., 2020a). In particular, derangements
of skeletal myocyte quality control mechanisms are thought
to play a relevant role in the development and progression
of age-related muscle wasting (Iqbal et al., 2013). Indeed,
altered recycling of damaged cell components and organelles
via autophagy, defective mitochondrial proteostasis and
dynamics, and impaired mitochondriogenesis have been
described in muscles of older adults with PF&S (Picca et al.,
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2018a). Systemic signatures of PF&S, including specific
inflammatory and amino acid profiles, have also been identified
(Calvani et al., 2018b, 2020a; Marzetti et al., 2019).
In the present study, we applied an innovative SO-CovSel–
LDA analytical approach to explore the relationship among
systemic inflammation, metabolic derangements, and circulating
MDVs in PF&S in order to provide hints on the underlying
pathogenic mechanisms. Among all assayed molecules, SO-
CovSel–LDA selected a panel comprising two amino acids (i.e.,
phosphoethanolamine and tryptophan), two cytokines (i.e., IL1-
ra and MIP-1β), and NDUFS3, a subunit of complex I of
the mitochondrial electron transport chain (ETC), as the best
predictors to discriminate older adults with and without PF&S.
The identification of phosphoethanolamine within the
discriminant metabolites for the classification of PF&S is
particularly relevant. Phosphoethanolamine is an ethanolamine
derivate produced as an intermediate of the CDP-ethanolamine
pathway involved in the metabolism of glycerophospholipid and
biological membrane turnover (Patel and Witt, 2017; van der
Veen et al., 2017). Disruption of CDP-ethanolamine pathway
has been associated with mitochondrial dyshomeostasis in
mouse models of muscle atrophy (Selathurai et al., 2019) and
insulin resistance (Funai et al., 2016). Phosphoethanolamine has
also been found to mediate mitochondrial membrane fusion
and curvatures and, in combination with ethanolamine, to
promote autophagy and longevity (Rockenfeller et al., 2015).
The difference in phosphoethanolamine serum levels between
older adults with and without PF&S might reflect impairment of
autophagy in the setting of muscle atrophy (Iqbal et al., 2013;
Marzetti et al., 2016). This hypothesis is in keeping with the
higher secretion of sEVs previously described in older adults
with PF&S (Picca et al., 2020a), which could be interpreted as
an attempt to cope with deficient MQC processes (Soubannier
et al., 2012; Picca et al., 2020b). Noticeably, derangements in
the MQC machinery were documented in intraoperative muscle
biopsies obtained from old hip-fractured patients with sarcopenia
(Marzetti et al., 2016). Finally, phosphoethanolamine was also
found among the mediators possibly involved in the disabling
cascade in frail older persons with type 2 diabetes mellitus
(T2DM) (Calvani et al., 2020b).
The amino acidic profile of participants with PF&S also
included the aromatic essential amino acid tryptophan. The
latter regulates several activities within the body, including
growth, mood, behavior, and immune responses (Le Floc’h et al.,
2011). Its metabolism is mediated by the tryptophan-kynurenine
and the tryptophan-methoxyndole pathways, leading to the
production of physiologically relevant bioactive compounds,
such as NAD, serotonin, and melatonin (Le Floc’h et al., 2011).
Changes in tryptophan circulating levels have been associated
with lowmuscle quality (Moaddel et al., 2016), insulin resistance,
and frailty in older adults with T2DM (Chen et al., 2016; Marcos-
Pérez et al., 2017; Calvani et al., 2020b).
As per the inflammatory fingerprint of PF&S, IL1-ra and
MIP-1β were selected by SO-CovSel–LDA as the most relevant
mediators. A frailty “cytokinome” in older adults with PF&S
composed of a “core” inflammatory profile with gender-
specific signatures was previously described by our group
(Marzetti et al., 2019). In a later study, SO-CovSel allowed
restricting to only MPO and platelet-derived growth factor BB
the mediators describing the contribution of inflammation to
PF&S (Calvani et al., 2020a). In the same study, gender-specific
models selected MIP-1β as one of the most relevant biomarkers
for the discrimination between PF&S and nonPF&S participants
(Calvani et al., 2020a). MIP-1β is a chemokine that regulates
myoblast response to muscle injury and promotes leucocyte
recruitment at the site of muscle damage (Yahiaoui et al., 2008).
The presence of MIP-1β among discriminant analytes for PF&S
may be interpreted as a compensatory action to impaired muscle
regenerative capacity (Calvani et al., 2020a). Inflamm-aging, the
chronic low-grade inflammation that develops during aging, has
been involved in the pathogenesis of sarcopenia and physical
disability (Wilson et al., 2017; Franceschi et al., 2018; Furman
et al., 2019). In this context can be framed the selection of IL1-ra
among the discriminant biomolecules associated with PF&S. IL1-
ra is a natural negative modulator of IL1α- and IL1β-mediated
inflammatory response and was found to be overexpressed in
muscles of older adults (Przybyla et al., 2006). The inflammatory
milieu of PF&S is also reflected by the higher neutrophil-to-
lymphocyte ratio, an easily accessible indicator of inflammation.
Finally, the MDV cargo molecule NDUFS3 was selected
among the discriminant mediators for PF&S. NDUFS3 is a
nuclear-encoded subunit of complex I of the mitochondrial
ETC. Mutations of NDUFS3 are associated with deficiency in
mitochondrial respiration and myopathies (Bénit et al., 2004;
Pereira et al., 2020). Conversely, NDUFS3 gene replacement
rescued muscle structure and mitochondrial in a mouse model
of mitochondrial myopathy (Pereira et al., 2020). Mitochondrial
dysfunction and insufficient MDV-mediated quality control have
also been hypothesized to contribute to PF&S (Picca et al., 2020a).
This idea is in keeping with the altered expression of key MQC
proteins described in muscles of old hip-fractured patients with
sarcopenia (Marzetti et al., 2016).
Taken as a whole, our findings provide preliminary, yet
novel insights into the relationship among metabolic changes,
inflamm-aging, and mitochondrial dyshomeostasis in PF&S. In
particular, the retrieval of MDVs in serum of older adults
with PF&S allows placing this process in the context of an
innate immune response as part of the “danger theory” of
inflammation (Zhang et al., 2010). According to this view, MDVs
may function as antigen-presenting vesicles carrying misplaced
noxious material. Similar to damage-associated molecular
patterns (DAMPs) released from injured cells, the MDV cargo
can trigger caspase-1 activation and the secretion of pro-
inflammatory cytokines (Krysko et al., 2011). This inflammatory
response would be mounted through the interactions of
mitochondrial DAMPs with receptors/systems including Toll-
like receptors, Nod-like receptor family pyrin domain containing
3 inflammasome, and cytosolic cyclic GMP–AMP synthase-
stimulator of interferon genes DNA sensing system (Picca et al.,
2017b). Impaired MQC in skeletal myocytes may therefore
install a vicious circle favoring further mitochondrial damage
and the propagation of sterile inflammation through DAMPs
release (Picca et al., 2018b). Should this hypothesis be confirmed,
the scavenging of circulating mitochondrial DAMPs might be
Frontiers in Cell and Developmental Biology | www.frontiersin.org 7 September 2020 | Volume 8 | Article 564417
Marzetti et al. Physical Frailty and Sarcopenia Biomarkers
exploited for the development of therapeutic interventions
for PF&S.
Albeit presenting promising findings, our work has limitations
that deserve discussion. First of all, the study was conducted in
a small participant sample and results need to be validated in
larger cohorts. Although participants were carefully selected and
thoroughly characterized, the chance of unknown comorbidities
affecting the results cannot be excluded. Also, the cross-
sectional design of the study hampers establishing cause-effect
or temporal relationships between the analyzed pathways and
PF&S development. Finally, while the biomarker panel analyzed
in the present study included a large number of biomolecules, the
possibility exists that a more comprehensive appraisal of PF&S
pathophysiology might be obtained through the analysis of larger
sets of mediators.
DATA AVAILABILITY STATEMENT
All datasets generated for this study are included in the
article/Supplementary Material.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Università Cattolica del Sacro Cuore, Rome, Italy.
The participants provided their written informed consent to
participate in this study.
AUTHOR CONTRIBUTIONS
APi, CB, EM, FG, and RC: conceptualization. APi and FG:
data curation. AB and FM: data analysis. APi, APr, FG, HC-
J, and JG: methodology. APi, EM, and RC: writing—original
draft preparation. CB, FG, and FL: writing—review and editing.
FL and RB: supervision. CB and RB: funding acquisition.
All authors contributed to the article and approved the
submitted version.
FUNDING
This work was supported by Innovative Medicine Initiative-Joint
Undertaking (IMI-JU #115621), AIRC (Associazione Italiana
per la Ricerca sul Cancro) Investigator grant 2016 #19068 to
CB, Ministero dell’Istruzione, dell’Università e della Ricerca
(MIUR) to Consorzio Interuniversitario Biotecnologie (DM
1049, 29/12/2018; CIB N. 112/19 to CB), intramural research
grants from the Università Cattolica del Sacro Cuore (D3.2
2013, D3.2 2015, and D3.2 2020), and the nonprofit research
foundation Centro Studi Achille e Linda Lorenzon.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fcell.2020.
564417/full#supplementary-material
REFERENCES
Addolorato, G., Ponziani, F. R., Dionisi, T., Mosoni, C., Vassallo, G. A., Sestito,
L., et al. (2020). Gut microbiota compositional and functional fingerprint in
patients with alcohol use disorder and alcohol-associated liver disease. Liver
Int. 40, 878–88. doi: 10.1111/liv.14383
Beaudart, C., Rizzoli, R., Bruyère, O., Reginster, J. Y., and Biver, E. (2014).
Sarcopenia: burden and challenges for public health. Arch Public Health 72:45.
doi: 10.1186/2049-3258-72-45
Bénit, P., Slama, A., Cartault, F., Giurgea, I., Chretien, D., Lebon, S., et al. (2004).
Mutant NDUFS3 subunit of mitochondrial complex I causes leigh syndrome. J.
Med. Genet. 41, 14–17. doi: 10.1136/jmg.2003.014316
Biancolillo, A., Boqué, R., Cocchi, M., and Marini, F. (2019). “Data
fusion strategies in food analysis,” in: Cocchi M, editor. Data
Fusion Methodology and Application. Oxford: Elsevier Ltd. 271–310.
doi: 10.1016/B978-0-444-63984-4.00010-7
Biancolillo, A., Marini, F., and Roger, J. M. (2020). SO-CovSel: a novel method
for variable selection in a multiblock framework. J. Chemom. 34:e3120.
doi: 10.1002/cem.3120
Biancolillo, A., and Næs, T. (2019). “The sequential and orthogonalized PLS
regression for multiblock regression: theory, examples, and extensions,” in:
Cocchi M, editor. Data Fusion Methodology and Application. Oxford: Elsevier
Ltd. 157–77.
Calvani, R., Marini, F., Cesari, M., Tosato, M., Anker, S. D., von Haehling,
S., et al. (2015). Biomarkers for physical frailty and sarcopenia: state of the
science and future developments. J. Cachexia Sarcopenia Muscle 6, 278–286.
doi: 10.1002/jcsm.12051
Calvani, R., Marini, F., Cesari, M., Tosato, M., Picca, A., Anker, S. D., et al. (2017).
Biomarkers for physical frailty and sarcopenia. Aging Clin. Exp. Res. 29, 29–34.
doi: 10.1007/s40520-016-0708-1
Calvani, R., Picca, A., Cesari, M., Tosato, M., Marini, F., Manes-Gravina, E., et al.
(2018a). Biomarkers for sarcopenia: reductionism vs. complexity. Curr. Protein
Pept. Sci. 19, 639–642. doi: 10.2174/1389203718666170516115422
Calvani, R., Picca, A., Marini, F., Biancolillo, A., Cesari, M., Pesce, V., et al. (2018c).
The “BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly
pErsons” (BIOSPHERE) study: rationale, design and methods. Eur. J. Intern.
Med. 56, 19–25. doi: 10.1016/j.ejim.2018.05.001
Calvani, R., Picca, A., Marini, F., Biancolillo, A., Gervasoni, J., Persichilli, S.,
et al. (2018b). A distinct pattern of circulating amino acids characterizes older
persons with physical frailty and sarcopenia: results from the BIOSPHERE
study. Nutrients 10:1691. doi: 10.3390/nu10111691
Calvani, R., Picca, A., Marini, F., Biancolillo, A., Gervasoni, J., Persichilli, S.,
et al. (2020a). Identification of biomarkers for physical frailty and sarcopenia
through a new multi-marker approach: results from the BIOSPHERE study.
GeroScience. doi: 10.1007/s11357-020-00197-x
Calvani, R., Rodriguez-Mañas, L., Picca, A., Marini, F., Biancolillo, A., Laosa,
O., et al. (2020b). Identification of a circulating amino acid signature in frail
older persons with type 2 diabetes mellitus: results from the Metabofrail study.
Nutrients 12:199. doi: 10.3390/nu12010199
Cesari, M., Landi, F., Calvani, R., Cherubini, A., Di Bari, M., Kortebein, P.,
et al. (2017). Rationale for a preliminary operational definition of physical
frailty and sarcopenia in the SPRINTT trial. Aging Clin. Exp. Res. 29, 81–88.
doi: 10.1007/s40520-016-0716-1
Chen, T., Zheng, X., Ma, X., Bao, Y., Ni, Y., Hu, C., et al. (2016). Tryptophan
predicts the risk for future type 2 diabetes. PLoS ONE 11:e0162192.
doi: 10.1371/journal.pone.0162192
Cohen, A. A., Legault, V., Fuellen, G., Fülöp, T., Fried, L. P., and Ferrucci, L. (2018).
The risks of biomarker-based epidemiology: associations of circulating calcium
levels with age, mortality, and frailty vary substantially across populations. Exp.
Gerontol. 107:11–17. doi: 10.1016/j.exger.2017.07.011
Frontiers in Cell and Developmental Biology | www.frontiersin.org 8 September 2020 | Volume 8 | Article 564417
Marzetti et al. Physical Frailty and Sarcopenia Biomarkers
Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., and Santoro, A. (2018).
Inflammaging: a new immune–metabolic viewpoint for age-related diseases.
Nat. Rev. Endocrinol. 14, 576–590. doi: 10.1038/s41574-018-0059-4
Funai, K., Lodhi, I. J., Spears, L. D., Yin, L., Song, H., Klein, S., et al. (2016). Skeletal
muscle phospholipid metabolism regulates insulin sensitivity and contractile
function. Diabetes 65, 358–370. doi: 10.2337/db15-0659
Furman, D., Campisi, J., Verdin, E., Carrera-Bastos, P., Targ, S., Franceschi, C.,
et al. (2019). Chronic inflammation in the etiology of disease across the life
span. Nat. Med. 25, 1822–1832. doi: 10.1038/s41591-019-0675-0
Guralnik, J. M., Simonsick, E. M., Ferrucci, L., Glynn, R. J., Berkman, L. F., Blazer,
D. G., et al. (1994). A short physical performance battery assessing lower
extremity function: association with self-reported disability and prediction
of mortality and nursing home admission. J. Gerontol. 49, M85–M94.
doi: 10.1093/geronj/49.2.M85
Iqbal, S., Ostojic, O., Singh, K., Joseph, A.-M., and Hood, D. A. (2013).
Expression of mitochondrial fission and fusion regulatory proteins in
skeletal muscle during chronic use and disuse. Muscle Nerve 48, 963–970.
doi: 10.1002/mus.23838
Justice, J. N., Ferrucci, L., Newman, A. B., Aroda, V. R., Bahnson, J.
L., Divers, J., et al. (2018). A framework for selection of blood-based
biomarkers for geroscience-guided clinical trials: report from the TAME
Biomarkers Workgroup. GeroScience 40, 419–436. doi: 10.1007/s11357-018-
0042-y
Krysko, D. V., Agostinis, P., Krysko, O., Garg, A. D., Bachert, C., Lambrecht,
B. N., et al. (2011). Emerging role DAMPs derived from mitochondria in
inflammation. Trends Immunol. 32, 157–164. doi: 10.1016/j.it.2011.01.005
Landi, F., Calvani, R., Cesari, M., Tosato, M., Maria Martone, A., Ortolani,
E., et al. (2018). Sarcopenia: an overview on current definitions,
diagnosis and treatment. Curr. Protein Pept. Sci. 19, 633–638.
doi: 10.2174/1389203718666170607113459
Le Floc’h, N., Otten, W., and Merlot, E. (2011). Tryptophan metabolism, from
nutrition to potential therapeutic applications. Amino Acids 41, 1195–1205.
doi: 10.1007/s00726-010-0752-7
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., and Kroemer, G. (2013).
The hallmarks of aging. Cell 153, 1194–1217. doi: 10.1016/j.cell.2013.05.039
Marcos-Pérez, D., Sánchez-Flores, M., Maseda, A., Lorenzo-López, L., Millán-
Calenti, J. C., Strasser, B., et al. (2017). Frailty Status in older adults is related
to alterations in indoleamine 2,3-dioxygenase 1 and guanosine triphosphate
cyclohydrolase I enzymatic pathways. J. Am. Med. Dir. Assoc. 18, 1049–1057.
doi: 10.1016/j.jamda.2017.06.021
Marzetti, E., Calvani, R., Landi, F., Hoogendijk, E., Fougère, B., Vellas, B., et al.
(2015). Innovative medicines initiative: the SPRINT project. J. Frailty Aging
4, 207–208. doi: 10.14283/jfa.2015.69
Marzetti, E., Calvani, R., Lorenzi, M., Tanganelli, F., Picca, A., Bossola,
M., et al. (2016). Association between myocyte quality control signaling
and sarcopenia in old hip-fractured patients: results from the Sarcopenia
in HIp FracTure (SHIFT) exploratory study. Exp. Gerontol. 80, 1–5.
doi: 10.1016/j.exger.2016.04.003
Marzetti, E., Calvani, R., Tosato, M., Cesari, M., Di Bari, M., Cherubini, A.,
et al. (2017). Sarcopenia: an overview. Aging Clin. Exp. Res. 29, 11–17.
doi: 10.1007/s40520-016-0704-5
Marzetti, E., Cesari, M., Calvani, R., Msihid, J., Tosato, M., Rodriguez-Mañas,
L., et al. (2018). The “Sarcopenia and Physical fRailty IN older people:
multi-componenT Treatment strategies” (SPRINTT) randomized controlled
trial: case finding, screening and characteristics of eligible participants. Exp.
Gerontol. 113, 48–57. doi: 10.1016/j.exger.2018.09.017
Marzetti, E., Picca, A.,Marini, F., Biancolillo, A., Coelho-Junior, H. J., Gervasoni, J.,
et al. (2019). Inflammatory signatures in older persons with physical frailty and
sarcopenia: the frailty “cytokinome” at its core. Exp. Gerontol. 122, 129–138.
doi: 10.1016/j.exger.2019.04.019
Moaddel, R., Fabbri, E., Khadeer, M. A., Carlson, O. D., Gonzalez-Freire, M.,
Zhang, P., et al. (2016). Plasma biomarkers of poor muscle quality in older men
and women from the Baltimore Longitudinal Study of Aging. J. Gerontol A Biol.
Sci. Med. Sci. 71, 1266–1272. doi: 10.1093/gerona/glw046
Newman, A. B., Simonsick, E. M., Naydeck, B. L., Boudreau, R. M., Kritchevsky,
S. B., Nevitt, M. C., et al. (2006). Association of long-distance corridor walk
performance with mortality, cardiovascular disease, mobility limitation, and
disability. J. Am. Med. Assoc. 295, 2018–2026. doi: 10.1001/jama.295.17.2018
Patel, D., and Witt, S. N. (2017). Ethanolamine and phosphatidylethanolamine:
partners in health and disease. Oxid. Med. Cell. Longev. 2017:4829180.
doi: 10.1155/2017/4829180
Pereira, C. V., Peralta, S., Arguello, T., Bacman, S. R., Diaz, F., and Moraes, C.
T. (2020). Myopathy reversion in mice after restauration of mitochondrial
complex I. EMBOMol. Med. 12:e10674. doi: 10.15252/emmm.201910674
Picca, A., Beli, R., Calvani, R., Coelho-Júnior, H. J., Landi, F., Bernabei, R., et al.
(2020a). Older adults with physical frailty and sarcopenia show increased
levels of circulating small extracellular vesicles with a specific mitochondrial
signature. Cells 9:973. doi: 10.3390/cells9040973
Picca, A., Calvani, R., Bossola, M., Allocca, E., Menghi, A., Pesce, V., et al. (2018a).
Update on mitochondria and muscle aging: all wrong roads lead to sarcopenia.
Biol. Chem. 399, 421–436. doi: 10.1515/hsz-2017-0331
Picca, A., Calvani, R., Lorenzi, M., Menghi, A., Galli, M., Vitiello, R., et al.
(2017a). Mitochondrial dynamics signaling is shifted toward fusion in
muscles of very old hip-fractured patients: results from the Sarcopenia
in HIp FracTure (SHIFT) exploratory study. Exp. Gerontol. 96, 63–67.
doi: 10.1016/j.exger.2017.06.005
Picca, A., Guerra, F., Calvani, R., Bucci, C., Lo Monaco, M. R., Bentivoglio, A.
R., et al. (2019b). Mitochondrial-derived vesicles as candidate biomarkers
in Parkinson’s disease: rationale, design and methods of the EXosomes
in PArkiNson Disease (EXPAND) study. Int. J. Mol. Sci. 20:2373.
doi: 10.3390/ijms20102373
Picca, A., Guerra, F., Calvani, R., Marini, F., Biancolillo, A., Landi, G., et al. (2020b).
Mitochondrial signatures in circulating extracellular vesicles of older adults
with Parkinson’s disease: results from the EXosomes in PArkiNson’s Disease
(EXPAND) study. J. Clin. Med. 9:504. doi: 10.3390/jcm9020504
Picca, A., Lezza, A. M. S., Leeuwenburgh, C., Pesce, V., Calvani, R., Bossola,
M., et al. (2018b). Circulating mitochondrial DNA at the crossroads of
mitochondrial dysfunction and inflammation during aging and muscle wasting
disorders. Rejuvenation Res. 21, 350–359. doi: 10.1089/rej.2017.1989
Picca, A., Lezza, A. M. S., Leeuwenburgh, C., Pesce, V., Calvani, R.,
Landi, F., et al. (2017b). Fueling inflamm-aging through mitochondrial
dysfunction: mechanisms and molecular targets. Int. J. Mol. Sci. 18:933.
doi: 10.3390/ijms18050933
Picca, A., Ponziani, F. R., Calvani, R., Marini, F., Biancolillo, A., Coelho-Junior,
H. J., et al. (2019a). Gut microbial, inflammatory and metabolic signatures in
older people with physical frailty and sarcopenia: results from the BIOSPHERE
study. Nutrients 12:65. doi: 10.3390/nu12010065
Ponziani, F. R., Bhoori, S., Castelli, C., Putignani, L., Rivoltini, L., Del Chierico, F.,
et al. (2019). Hepatocellular carcinoma is associated with gut microbiota profile
and inflammation in nonalcoholic fatty liver disease. Hepatology 69, 107–120.
doi: 10.1002/hep.30036
Ponziani, F. R., Putignani, L., Paroni Sterbini, F., Petito, V., Picca, A., Del Chierico,
F., et al. (2018). Influence of hepatitis C virus eradication with direct-acting
antivirals on the gut microbiota in patients with cirrhosis. Aliment Pharmacol.
Ther. 48, 1301–1311. doi: 10.1111/apt.15004
Przybyla, B., Gurley, C., Harvey, J. F., Bearden, E., Kortebein, P., Evans, W. J., et al.
(2006). Aging alters macrophage properties in human skeletal muscle both at
rest and in response to acute resistance exercise. Exp. Gerontol. 41, 320–327.
doi: 10.1016/j.exger.2005.12.007
Rockenfeller, P., Koska, M., Pietrocola, F., Minois, N., Knittelfelder, O., Sica, V.,
et al. (2015). Phosphatidylethanolamine positively regulates autophagy and
longevity. Cell Death Differ. 22, 499–508. doi: 10.1038/cdd.2014.219
Roger, J. M., Palagos, B., Bertrand, D., and Fernandez-Ahumada, E. (2011). CovSel:
Variable selection for highly multivariate and multi-response calibration.
Application to IR spectroscopy. Chemom. Intell. Lab. Syst. 106, 216–223.
doi: 10.1016/j.chemolab.2010.10.003
Selathurai, A., Kowalski, G. M., Mason, S. A., Callahan, D. L., Foletta, V. C., Della
Gatta, P. A., et al. (2019). Phosphatidylserine decarboxylase is critical for the
maintenance of skeletal muscle mitochondrial integrity and muscle mass.Mol.
Metab. 27, 33–46. doi: 10.1016/j.molmet.2019.06.020
Sierra, F. (2016). The emergence of geroscience as an interdisciplinary approach to
the enhancement of health span and life span. Cold Spring Harb. Perspect. Med.
6:a025163. doi: 10.1101/cshperspect.a025163
Smit, S., van Breemen, M. J., Hoefsloot, H. C. J., Smilde, A. K., Aerts, J. M. F. G.,
and de Koster, C. G. (2007). Assessing the statistical validity of proteomics based
biomarkers. Anal. Chim. Acta 592, 210–217. doi: 10.1016/j.aca.2007.04.043
Frontiers in Cell and Developmental Biology | www.frontiersin.org 9 September 2020 | Volume 8 | Article 564417
Marzetti et al. Physical Frailty and Sarcopenia Biomarkers
Soubannier, V., McLelland, G.-L., Zunino, R., Braschi, E., Rippstein, P., Fon, E. A.,
et al. (2012). A vesicular transport pathway shuttles cargo from mitochondria
to lysosomes. Curr. Biol. 22, 135–141. doi: 10.1016/j.cub.2011.11.057
Studenski, S. A., Peters, K. W., Alley, D. E., Cawthon, P. M., McLean, R. R., Harris,
T. B., et al. (2014). The FNIH sarcopenia project: rationale, study description,
conference recommendations, and final estimates. J. Gerontol. A Biol. Sci. Med.
Sci. 69, 547–558. doi: 10.1093/gerona/glu010
Théry, C., Amigorena, S., Raposo, G., and Clayton, A. (2006). Isolation
and characterization of exosomes from cell culture supernatants and
biological fluids. Curr. Protoc. Cell Biol. 3:22. doi: 10.1002/0471143030.cb0
322s30
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D.,
Andriantsitohaina, R., et al. (2018). Minimal information for studies
of extracellular vesicles 2018 (MISEV2018): a position statement of the
International Society for Extracellular Vesicles and update of the MISEV2014
guidelines. J. Extracell Vesicles 7:1535750. doi: 10.1080/20013078.2018.
1535750
van der Veen, J. N., Kennelly, J. P., Wan, S., Vance, J. E., Vance, D.
E., and Jacobs, R. L. (2017). The critical role of phosphatidylcholine
and phosphatidylethanolamine metabolism in health and disease. Biochim.
Biophys. Acta Biomembr. 1859, 1558–1572. doi: 10.1016/j.bbamem.2017.
04.006
Westerhuis, J. A., Hoefsloot, H. C. J., Smit, S., Vis, D. J., Smilde, A. K., van Velzen,
E. J. J., et al. (2008). Assessment of PLSDA cross validation. Metabolomics 4,
81–89. doi: 10.1007/s11306-007-0099-6
Wilson, D., Jackson, T., Sapey, E., and Lord, J. M. (2017). Frailty and sarcopenia:
the potential role of an aged immune system. Ageing Res. Reviews 36, 1–10.
doi: 10.1016/j.arr.2017.01.006
Yahiaoui, L., Gvozdic, D., Danialou, G., Mack, M., and Petrof, B. J. (2008). CC
family chemokines directly regulate myoblast responses to skeletal muscle
injury. J. Physiol. 586, 3991–4004. doi: 10.1113/jphysiol.2008.152090
Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., et al. (2010).
Circulating mitochondrial DAMPs cause inflammatory responses to injury.
Nature 464, 104–107. doi: 10.1038/nature08780
Conflict of Interest: EM served as a consultant for Abbott, Biophytis, Nutricia,
and Nestlè. RC served as a consultant for Abbott and Nutricia.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
The handling editor declared a past co-authorship with several of the authors EM,
RC, and AP.
The reviewers FS and EP declared a past collaboration with one of the authors EM
to the handling editor.
Copyright © 2020 Marzetti, Guerra, Calvani, Marini, Biancolillo, Gervasoni,
Primiano, Coelho-Júnior, Landi, Bernabei, Bucci and Picca. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 10 September 2020 | Volume 8 | Article 564417
